Login to Your Account



Eloctate approval 'another incremental driver' for Biogen Idec

By Marie Powers
Staff Writer

Tuesday, June 10, 2014
FDA approval of Biogen Idec's long-acting hemophilia A product upped the ante in the space, as Eloctate (antihemophilic factor [recombinant], Fc fusion protein) became the first recombinant hemophilia A therapy with prolonged circulation in the body and the only treatment indicated to reduce the frequency of bleeding episodes in the indication by offering prophylactic infusions every three to five days.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription